Arca
Skip to content
Tools
Tools

ITGA4, ITGB7: Integrin alpha-4/beta-7

Complex in Homo sapiens that 4 drugs act on.

  • Drugs that act on it: 4
  • Approved: 2
  • In phases 1 to 3: 2
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on ITGA4, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1
  • Antibody 3

Approved2

  • Vedolizumab
  • Natalizumab

Phase 30

    Phase 22

    • Abrilumab
    • Firategrast

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 4 act as: Integrin alpha-4/beta-7 inhibitor; the rest name their own mechanism.
      VedolizumabApprovedTakeda Pharmaceuticals USAAntibodyInhibitor63
      NatalizumabBoxed warningApprovedBiogenAntibodyInhibitor11
      AbrilumabPhase 2AmgenAntibodyInhibitor0
      FirategrastPhase 2GSKSmall moleculeAntagonistIntegrin alpha-4/beta-7 antagonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.
      Non-Invasive Biomarker Monitoring in UC on BiologicsVedolizumab—Not yet recruitingUniversity Hospitals Coventry and Warwickshire NHS TrustNov 5, 2026
      REAL-MS: Observational Database Study of AHSCT and MS TherapiesNatalizumab—RecruitingImperial College LondonOct 27, 2026
      Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyNatalizumabPhase 2RecruitingUniversity of Michigan Rogel Cancer CenterOct 23, 2026
      Immune Aging and Advanced Therapy Outcomes in Older Adults With IBDVedolizumab—Not yet recruitingFirst Affiliated Hospital, Sun Yat-Sen UniversitySep 18, 2026
      Ex Vivo Comparison Of Combination Versus Single Therapeutic Pathway Inhibition In Human Intestinal Mucosa From Patients With Inflammatory Bowel DiseaseVedolizumabNot applicableNot yet recruitingPhoenixLAB srlsSep 17, 2026
      Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's DiseaseVedolizumab—RecruitingShanghai 10th People's HospitalJul 10, 2026
      Combination CurQD and Vedolizumab in Ulcerative ColitisVedolizumabPhase 4Not yet recruitingRyan C UngaroJun 24, 2026
      PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid ExposureVedolizumabPhase 2Not yet recruitingTherakos LLCJun 2, 2026
      FirST Lines of Biologics in pAtients With ulceRaTivE Colitis: a Randomised Controlled TrialVedolizumabPhase 4Not yet recruitingUniversity Hospital, Clermont-FerrandMay 8, 2026
      Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper EgyptVedolizumab—Not yet recruitingAssiut UniversityMar 27, 2026
      Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and SerologicNatalizumabNot applicableRecruitingUniversity Hospital, MontpellierJul 27, 2023
      A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesNatalizumab—Active, not recruitingBiogenJan 18, 2023
      Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)Natalizumab—RecruitingBiogenDec 20, 2022
      Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)NatalizumabPhase 2RecruitingQueen Mary University of LondonJun 14, 2022
      Covid-19 Vaccine Immune Response in Multiple SclerosisNatalizumab—Active, not recruitingUniversity Hospitals of North Midlands NHS TrustMar 8, 2022
      Cladribine Tablets After Treatment With Natalizumab (CLADRINA)NatalizumabPhase 4Active, not recruitingUniversity of Texas Southwestern Medical CenterNov 26, 2019

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095184, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.